Universität zu Köln

Persigehl, Thorsten, Lennartz, Simon and Schwartz, Lawrence H. (2020). iRECIST: how to do it. Cancer Imaging, 20 (1). LONDON: BMC. ISSN 1470-7330

Full text not available from this repository.

Abstract

Background iRECIST for the objective monitoring of immunotherapies was published by the official RECIST working group in 2017. Main body Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multiple malignant diseases especially at advanced, metastatic stages which were poorly therapeutically accessible in the past. Promising results of recent studies suggest that their application will further grow in the near future, particularly when used in combination with chemotherapy. A challenging aspect of these immunotherapies is that they may show atypical therapy response patterns such as pseudoprogression and demonstrate a different imaging spectrum of adverse reactions, both of which are crucial for radiologists to understand. In 2017 the RECIST working group published a modified set of response criteria, iRECIST, for immunotherapy, based on RECIST 1.1 which was developed for cytotoxic therapies and adapted for targeted agents. Conclusion This article provides guidance for response assessment of oncologic patients under immunotherapy based on iRECIST criteria.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Persigehl, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Lennartz, Simon UNSPECIFIED UNSPECIFIED UNSPECIFIED Schwartz, Lawrence H. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-349238
DOI:	10.1186/s40644-019-0281-x
Journal or Publication Title:	Cancer Imaging
Volume:	20
Number:	1
Date:	2020
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1470-7330
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IMMUNE-RELATED RESPONSE; CELL LUNG-CANCER; CHECKPOINT INHIBITORS; NIVOLUMAB; THERAPY; PSEUDOPROGRESSION; GUIDELINES; CARCINOMA; SURVIVAL; CRITERIA Multiple languages Oncology; Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/34923